Optimization of a pharmacokinetic assay in a bridging assay format using the Gyrolab immunoassay platform
Anti-TNF alpha antibodies were among the first approved antibody drugs and now belongs to the best-selling drugs. Today, several companies are developing biosimilars to those drugs which will increase the access of medications and potentially reduce health care costs. There is a great demand for pha...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | English |
| Published: |
Uppsala universitet, Biokemi
2019
|
| Subjects: | |
| Online Access: | http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-396493 |